on the ability of the child. Refraction and other eye abnormalities were also recorded.
Retinopathy of prematurity (ROP) is a leading cause of childhood blindness.' 2 Cryotherapy was first used in the treatment of this condition in the 1970s.3456 However the methods of application and the overall success rate differed.78910 To standardise treatment the multicentre North American Cryotherapy for Retinopathy Study Group trial (CRYOROP) was established in 1986 and the results, published in 1988," showed that the incidence of an unfavourable outcome could be reduced from 43% to 21-5% in treated cases. We present our own experience and results in a prospective study of children treated since 1986. on the ability of the child. Refraction and other eye abnormalities were also recorded.
Results
Thirteen eyes regressed to normal with peripheral cryotherapy scars only, 11 eyes developed cicatricial disease following treatment, five of these have ectopic maculae and dragging of the disc, six progressed to total retinal detachment. Two of the six eyes had stage 4a disease at the time of treatment, four had vitreoretinal surgery with one retina reattaching after surgery ( Table 1) .
The visual outcome is summarised in 
Discussion
The current theory for the development of ROP is the release of a vasoproliferative factor from the anterior avascular retina which stimulates neovascularisation.2 Cryotherapy to the ischaemic retina, which is thought to reduce the formation of this vasoproliferative factor,'3 is presently the only effective treatment in established ROP. Therefore effective screening and proper staging are essential. In our unit we screen all infants under 1500 g and under 30 weeks of gestation. We perform the first examination at 6 weeks using the indirect ophthalmoscope and eye speculum. The pupil is widely dilated using 0 5% cyclopentolate and 2-5% phenylephrine.
While we have in the main adopted the CRYOROP criteria treating stage 3 threshold disease, we have treated both eyes in some children and stage 4 in one child. We have used gestational age only in this prospective study. Others'4 have highlighted the concept of postmenstrual or postconceptual age which is calculated as the sum of the gestational age at birth plus the postnatal age at which retinopathy is discovered. They raised the interesting concept that the age at which ROP is first seen is controlled by the stage of retinal development rather than neonatal events.
The CRYOROP group defined a structural unfavourable outcome as (1) a retinal fold involving the macula, and (2) We realise the inaccuracy of our crude visual estimations; however fixation patterns in young infants have been shown to correlate with final visual outcome. 17 It is also important to emphasise that these visions have not been matched with age norms and this will be the subject of a longer follow-up study. Despite these limitations our results highlight a better visual outcome in eyes with normal posterior poles and a poorer outcome in eyes with cicatricial disease, although some maintain at least navigational vision.
The effect ofcryotherapy on the final refractive error also needs to be determined by long-term follow-up. It has been suggested that cryotherapy may increase myopia. 8 In this study the eyes with normal posterior poles have refractive errors which range across the board with high myopia in only one child. Those with cicatrical disease, where it was possible to measure refraction, all have myopia. While our numbers are too small to determine statistical significance perhaps it is reasonable to propose that it is the end point of the disease rather than cryotherapy which determines eye growth and the ultimate refractive error.
We applied cryotherapy under general anaesthesia in contrast to the CRYOROP group where general anaesthesia was used in only 27% of cases. We are better able to apply cryopexy in this environment and our anaesthetist and neonatologist is happier with this approach. Apart from chemosis and retinal haemorrhage which spontaneously resolved, the most severe complication was the development of a retrolental membrane and total retinal detachment 2 months following successful cryoapplication in one eye. This eye showed regression of ROP 2 weeks post treatment. This possibly may have been due to the cryotherapy itself rather than progression of ROP. The CRYOROP trial reported ocular complications such as conjunctival haematoma and laceration, retinal, preretinal, and vitreous haemorrhage. Systemic complications in the same group included bradycardia, arrhythmias, and significant apnoea. Brown'9 reported a series with respiratory and cardiorespiratory arrest. In our study cryopexy was applied under general anaesthesia in 14 infants, requiring assisted ventilation in two infants only.
Recently indirect laser therapy to the avascular retina has been advocated as an alternative to cryotherapy.20 Its advantages include greater control over the degree of ablative therapy required. However it involves an expensive outlay for a new laser system. Cryotherapy is inexpensive, more mobile, widely available, and relatively easy to apply. In our view it will remain the treatment of choice in most centres for the foreseeable future.
In summary cryotherapy works and is presently the most effective weapon in our fight against blindness in ROP. We feel this study is important as it includes not only children with normal posterior poles but also children with cicatricial disease who have maintained navigational vision or better, after cryopexy, who might otherwise have gone blind. The present concept of threshold disease as the cutoff point for treatment of ROP was determined by consensus rather than by scientific data. We feel this criterion may need to be reviewed.
